Enhanced Microglial Engulfment of Dopaminergic Synapses Induces Parkinson's Disease-Related Executive Dysfunction in

Yehao Liu1,2, Rui Chen1,3, Chunyan Mu1

  • 1Department of Neurobiology, Xuzhou Key Laboratory of Neurobiology, Xuzhou Medical University, Xuzhou, Jiangsu, China.

Aging Cell
|February 15, 2025
PubMed

Insights

Lysophosphatidylcholine (LPC) accumulation in Parkinson's disease (PD) drives microglial engulfment of dopaminergic synapses, causing executive dysfunction (EDF). Inhibiting this process and restoring dopamine signaling improves cognitive function in PD.

Area of Science:

  • Neuroscience
  • Pathophysiology
  • Molecular Biology

Background:

  • Dopaminergic VTA-mPFC pathway dysfunction is key in Parkinson's disease (PD) with executive dysfunction (EDF).
  • Elevated lysophosphatidylcholine (LPC) levels correlate with cognitive impairment severity in PD patients.

Purpose of the Study:

  • To investigate the role of LPC in PD-associated EDF.
  • To elucidate the molecular mechanisms linking LPC, microglial activation, and dopaminergic synaptic loss.

Main Methods:

  • Analysis of LPC levels in PD patients.
  • In vitro and in vivo studies using LPC-exposed mice.
  • Chemogenetic inhibition of microglial activation.
  • Assessment of dopaminergic synapse phagocytosis.
  • Evaluation of miR-2885/TDP-43/p65 signaling pathway.
  • Dopamine receptor agonist administration.

Main Results:

  • LPC disrupts miR-2885/TDP-43 pathway in microglia, promoting dopaminergic synapse engulfment via TDP-43/p65 signaling.
  • Microglial activation releases inflammatory factors, marking synapses for phagocytosis.
  • Inhibition of LPC-induced microglial activation and TDP-43 levels ameliorated EDF.
  • Dopamine receptor agonists improved executive function by enhancing glutamatergic neuron excitability.

Conclusions:

  • LPC-induced microglial dysfunction and subsequent dopaminergic synaptic loss contribute to EDF in PD.
  • Targeting LPC-mediated pathways and enhancing dopaminergic signaling offers potential therapeutic strategies for PD-associated cognitive deficits.